Alex Goldberg

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Autodesk, Inc. (NASDAQ:ADSK) Added to Equity Profile Report's NASDAQ Active Stock Watch List.

 
Repost This

Wilmington, DE -- (SBWIRE) -- 01/13/2014 -- Equity Profile Report expands its NASDAQ Active Stock Watch List adding Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Autodesk, Inc. (NASDAQ:ADSK) .

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) a biopharmaceutical company that engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases is currently up (+2.98%) on 10,124,578 shares traded after ARENA PHARMACEUTICALS INC Filed SEC form 8-K, Other Events. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is currently up (+70.86%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)

Autodesk, Inc. (NASDAQ:ADSK) operates as a design software and services company worldwide is currently down (-0.19%) on 3,792,394 shares traded. Autodesk, Inc. (NASDAQ:ADSK) is currently down (-2.64%) from its recent 52-week high which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List.

Click Here to find out what other Investors are saying about Autodesk, Inc. (NASDAQ:ADSK)

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.

Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com

Disclosure
Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com